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Abstract
Osteocytes play a critical role in mediating cell-cell communication and regulating bone 
homeostasis, and osteocyte apoptosis is associated with increased bone resorption. miR21, an 
oncogenic microRNA, regulates bone metabolism by acting directly on osteoblasts and 
osteoclasts, but its role in osteocytes is not clear. Here, we show that osteocytic miR21 deletion 
has sex-divergent effects in bone. In females, miR21 deletion reduces osteocyte viability, but 
suppresses bone turnover. Conversely, in males, miR21 deletion increases osteocyte viability, but 
stimulates bone turnover and enhances bone structure. Further, miR21 deletion differentially alters 
osteocyte cytokine production in the two sexes. Interestingly, despite these changes, miR21 
deletion increases bone mechanical properties in both sexes, albeit to a greater extent in males. 
Collectively, our findings suggest that miR21 exerts both sex-divergent and sex-equivalent roles in 
osteocytes, regulating osteocyte viability and altering bone metabolism through paracrine actions 
on osteoblasts and osteoclasts differentially in males vs. females, whereas, influencing bone 
mechanical properties independent of sex.
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Introduction
Osteocytes are the most prevalent and long-living type of cell in bone [1]. Extensive 
evidence suggests that osteocytes embedded in the bone matrix are targets of bone acting 
stimuli, and that osteocyte lifespan affects skeletal homeostasis [2-5]. Osteocytes regulate 
bone remodeling by modulating osteoclasts and osteoblasts through direct cell-cell 
interactions and via extracellular signaling through the release of soluble factors [1,6]. 
Additionally, osteocyte viability is reduced in conditions of increased bone fragility [7,8,4,9] 
and conversely, agents that preserve bone strength prevent osteocyte apoptosis [2-5]. 
Moreover, osteocyte apoptosis and the prevalence of empty lacunae are increased in old 
mice and humans [10,11]. However, the molecular mechanisms that lead to increased 
osteocyte apoptosis and the osteocyte-derived signaling factors that control bone metabolism 
in old age are not completely understood.
Recent work has identified microRNAs (miRs) as negative regulators of gene expression 
[12]. miRs are ~18-22-nucleotide long noncoding RNAs that regulate a plethora of cellular 
processes and dysregulation of particular miRs have been associated with numerous human 
diseases. Changes in miR expression can also contribute to the effects of aging in several 
organs [13]. In particular, alterations in miR21 abundance, a miR predominantly regarded as 
pro-survival and oncogenic, have been detected in numerous pathologies. In bone, miR21 
has been shown to directly regulate osteoblast and osteoclast differentiation and function 
[14]. However, the role of miR21 in osteocytes and its effects on bone turnover remain 
unclear.
We previously demonstrated several putative pro-survival miRs are dysregulated in MLO-Y4 
osteocytic cells in the absence of Cx43. In particular, miR21 levels are significantly 
decreased in Cx43-deficient cells, which undergo spontaneous apoptosis in culture; and 
addition of a miR21 mimic sufficiently restores the viability of these cells [15]. Conversely, 
inhibition of miR21 induces osteocyte apoptosis in control MLO-Y4 osteocytic cells. 
Further, we found that bones from mice lacking osteocytic Cx43 and from old female mice 
express lower levels of miR21 compared to control Cx43f/f and young mice, respectively 
[16]. Based on these findings and the notion that osteocyte apoptosis triggers osteoclast 
differentiation and recruitment [17], a simplistic model would predict apoptotic effects on 
osteocytes upon miR21 deletion, with subsequent increases in bone resorption and decreases 
bone strength. However, given the complex nature of miR regulation, both intra- and 
extracellular, in nearly every cell in the body, it should not have been surprising that this 
hypothesis was overly simplistic. Here, we provide experimental evidence that in vivo 
effects of the miR21 locus are more nuanced, and identify for the first time a sex-divergent 
impact of miR21 on osteocyte biology. We show that miR21 regulates osteocyte viability in 
a sex-dependent manner, preserving osteocyte viability in females but reducing osteocyte 
viability in males. Further, we demonstrate that osteocytic miR21 regulates osteocyte 
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cytokine production and bone turnover in a sex-specific manner. In particular, we found 
miR21 deletion differentially altered osteocyte cytokine production, as well as, several 
related signaling pathways in females and males. Despite these changes, miR21 deletion 
enhanced bone mechanical properties in both sexes, albeit to a greater extent in males. Taken 
together, these results suggest that miR21 exerts a sex-divergent role in osteocytes, 
regulating bone mass and architecture through non-cell autonomous effects on osteoblasts 
and osteoclasts, whereas, miR21 has sex-equivalent effects on bone mechanical properties.
Results
miR21 regulation of osteocyte viability and mitochondrial function is sex-dependent.
To investigate the role of osteocytic miR21 locus in vivo, we generated a mouse model in 
which miR21 was deleted from osteocytes (Fig. 1a). Targeted-deletion of miR21 in 
osteocytes decreased miR21 levels ~50% in calvaria bone lysates of both female and male 
miR21Δot compared to control miR21f/f mice (Fig. 1b). On the other hand, no significant 
changes in miR21 levels were found in the gastrocnemius muscle of male or female mice, 
even though reporter studies showed that skeletal muscle expressed the Cre recombinase 
under the DMP1-8kb promoter [18] (not shown). Interestingly, basal miR21 levels were 
higher in miR21f/f females than males, suggesting a sex-related difference in miR21 
expression in bone. Additionally, we detected decreases in mRNA levels of vacuole 
membrane protein-1 (VMP1) in both female and male miR21Δot compared to control 
miR21f/f mice, due to overlap between miR21 and the 3’ UTR of VMP1 (Fig. 1b). However, 
no sex-specific differences in VMP1 expression were detected in control mice. Further, 
VMP1 levels were not altered by inhibition or overexpression of miR21 in osteocytic MLO-
Y4 cells (not shown), suggesting that the effect of miR21 deletion in vivo on RANKL/OPG 
levels and on cell viability are a direct consequence of reduced miR21 levels and not of 
changes in VMP1 expression.
Similar to our previous findings in Cx43-deficient osteocytic cells [15], in females, the 
RANKL/OPG mRNA ratio was increased in bones from miR21Δot compared to miR21f/f 
mice (Fig. 1c). Additionally, female miR21Δot mice exhibited higher expression of the 
apoptosis-associated gene P27, as well as tendencies towards higher Gadd153 and Foxo3 
(Fig. 1d). Moreover, miR21 inhibition in control MLO-Y4 osteocytic cells, which are 
derived from a female mouse, increased the RANKL/OPG mRNA ratio and the expression 
of the apoptosis associated-genes (P27, Gadd153, and Foxo3) (Fig. 2a). Conversely, 
transfection of a miR21 mimic decreased the RANKL/OPG mRNA levels and apoptosis-
related gene expression (Fig. 2b). Further, miR21 inhibition increased the expression of 
apoptosis-associated genes (Fig. 2c) whereas miR21 overexpression, attenuated the 
increased RANKL/OPG mRNA ratio and apoptosis associated-gene expression (Fig. 2d) in 
Cx43-deficient MLO-Y4 cells, which exhibit increased levels of apoptosis and express low 
levels of miR21 compared to scramble-silenced cells [15].
While no changes in RANKL or OPG gene expression were detected in the miR21Δot 
compared to miR21f/f males (Fig. 1e), interestingly, our findings suggest that miR21 
negatively regulates osteocyte viability. Specifically, miR21Δot males exhibited lower levels 
of the apoptosis-associated genes (p27, Gadd153 and Foxo3) (Fig. 1f). Consistent with the 
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sex-divergent effects of osteocytic miR21 deletion on the apoptosis-associated genes and 
RANKL/OPG mRNA levels, miR21 deletion differentially altered mitochondrial gene 
expression in females and males. Specifically, miR21Δot females, but not males exhibited 
significantly lower levels of several mitochondria-associated genes, whereas in males, the 
expression of ND2 was increased (Fig. 3a,b).
Removal of osteocytic miR21 differentially regulates bone turnover in females and males.
To determine whether removal of osteocytic miR21 also regulates bone mass and bone cell 
activity in a sex-dependent manner, we next examined the bone phenotype of miR21Δot and 
miR21f/f mice of each sex. In females, deletion of miR21 from osteocytes did not alter the 
distribution of cartilage and mineralized bone in newborn mice (Fig. 4a). Similarly, total, 
spinal and femoral BMD were not affected by miR21 deletion in females up to 4 months of 
age, although slight increases in body weight were detected between 2 and 4 months of age 
in miR21Δot compared to miR21f/f mice (Fig. 4b). On the other hand, in males, total, spinal 
and femoral BMD were all significantly increased by 4 months of age in miR21Δot 
compared to miR21f/f mice, while body weight was unaltered (Fig. 4c).
Osteocytic miR21 deletion led to sex-specific changes in bone cell activity and bone 
geometry in both cortical and cancellous bone compartments. In females, dynamic bone 
histomorphometry analysis of the femur mid-diaphysis showed that, while the bone 
formation parameters on the periosteal surface were not changed, MS/BS (the mineralized 
surface per total bone surface) and BFR/BS (bone formation rate per bone surface) were 
significantly lower on the endocortical surface in miR21Δot compared to miR21f/f mice (Fig. 
5a). Conversely, in males, dynamic histomorphometry analysis of the femur mid-diaphysis 
showed that all bone formation measurements, MAR (mineral apposition rate), MS/BS, and 
BFR/BS, were increased on the periosteal surface, whereas no changes in bone formation 
were detected on the endocortical surface (Fig. 5b). Further, static histomorphometry 
analysis of the endocortical femur surface in females revealed a reduction in osteoclast 
number and surface per bone surface (N.Oc/BS and Oc.S/BS) in miR21Δot compared to 
miR21f/f mice (Fig. 5c). Consistent with the histomorphometric findings in cortical bone, 
decreases in circulating serum levels of the bone turnover makers, CTX, P1NP, and ALP 
were also detected in the female miR21Δot compared to miR21f/f mice (Fig. 6). In contrast to 
the reduced osteoclasts parameters in the miR21Δot females, in males, N.Oc/BS and 
Oc.S/BS were higher in the miR21Δot compared to miR21f/f mice (Fig. 5d).
Consistent with the sex-related alterations in bone cell activity induced by osteocytic miR21 
deletion, sex-dependent changes in femur cortical bone geometry were also revealed by μCT 
analysis of the femur mid-diaphysis. In females, the suppressed endocortical bone turnover 
did not alter cortical bone geometry (Fig. 5e), whereas in males, the μCT parameters, tissue 
area (TA), bone area (BA), cortical thickness (C.Th), marrow cavity area, and moment of 
inertia were all increased in miR21Δot compared to miR21f/f mice (Fig. 5f).
Sex-dependent alterations in bone turnover and architecture were also detected on cancellous 
surfaces within the vertebra. However, unlike the decrease in formation detected on the 
endocortical femur surface in females, removal of osteocytic miR21 did not alter cancellous 
osteoblast number or activity (Fig. 7a,b). On the other hand, reductions in Oc.S/BS were 
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detected on the cancellous surface of miR21Δot compared to miR21f/f female mice, while 
N.Oc/BS was unchanged (Fig. 7c). In males, no significant changes in cancellous osteoblast 
number or surface per cancellous bone surface (N.Ob/BS and Ob.S/BS) were detected in 
miR21Δot compared to miR21f/f mice (Fig. 7d). However, the dynamic histomorphometry 
bone formation parameter MS/BS was significantly higher in the male miR21Δot mice, 
suggestive of higher amounts of bone forming surface (Fig. 7e). Similar to N.Ob/BS and 
Ob.S/BS, no significant differences in vertebral cancellous N.Oc/BS and Oc.S/BS were 
detected in the male miR21Δot compared to the miR21f/f mice (Fig. 7f).
Despite the small changes in cancellous bone cell activity, μCT analysis detected significant 
alterations in cancellous bone architecture. In females, μCT of the vertebra revealed a slight 
increase in Tb.th (trabecular thickness) (Fig. 7g). On the other hand, in males μCT analysis 
detected significant increases in almost all the vertebral cancellous architecture parameters 
examined, including BV/TV (bone volume/tissue volume), Tb.Th, Tb.N (trabecular 
number), and material density miR21Δot compared to miR21f/f mice (Fig. 7h). Similar 
alterations in cancellous architecture of the distal femur were also detected in female and 
male miR21Δot compared to miR21f/f mice (Fig. 8).
Sex-divergent miR21 regulation of osteocyte cytokine production and release differentially 
controls osteoclastogenesis.
Consistent with the in vivo decreases in osteoclast number and surface in the miR21Δot 
compared to miR21f/f female mice, less mature osteoclasts were generated in vitro from 
female miR21Δot compared to miR21f/f non-adherent BMCs (Fig. 9a). On the other hand, in 
vitro generation of mature osteoclasts from male miR21Δot and miR21f/f non-adherent 
BMCs did not differ (Fig. 9b).
To further examine the mechanisms underlying the sex-specific osteoclast effects of 
osteocytic miR21 removal, we generated osteoclasts from wildtype BMCs cultured with CM 
from osteocyte-enriched miR21Δot and miR21f/f bone cultures, as illustrated in Fig. 9c. 
Consistent with our in vivo results, addition of 50% CM from miR21Δot females led to 0.7-
fold less mature osteoclasts (Fig. 9d), while addition of only 25% CM was not sufficient to 
reduce osteoclast number or gene expression (Fig. 10a). Conversely, addition of 50% CM 
from miR21Δot males led to 3.8-fold more osteoclasts that were larger in size (Fig 9e), and 
addition of 25% CM led to a tendency towards increase in osteoclast number and 
significantly increased osteoclast gene expression (Fig. 10b).
Next, we investigated the effects of osteocytic miR21 deficiency on osteocyte cytokine 
production and release. Consistent with the sex-dimorphic effects on osteoclastogenesis, 
mRNA levels of several pro-osteoclastogenic cytokines, IL-6, MCP-1, M-CSF, and VEGF-A 
were reduced in bone lysates from female, but not male miR21Δot compared to miR21f/f 
mice (Fig. 9f,g). Further, osteocytic-miR21 deletion induced sex-specific inflammatory 
cytokine protein alterations in CM from marrow-flushed osteocyte-enriched bone. In CM 
from miR21Δot female bones, M-CSF and VEGF protein levels showed tendencies towards 
decrease, whereas, in CM from miR21Δot male bones, M-CSF and VEGF protein levels 
were increased, although MCP-1 levels were decreased (Fig. 9h,I ). Interestingly, in serum 
from these mice, an opposite pattern of expression was observed for several inflammatory 
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cytokines altered in CM from miR21Δot bones (Tables 1,2). These pieces of evidence 
suggest that removal of osteocytic miR21 alters osteoclastogenesis by modifying osteocyte-
derived inflammatory cytokine production and release in the local bone microenvironment, 
as illustrated in Fig. 9j.
In addition, we detected sex-dependent decreases in the mRNA levels of several cytokines 
known to inhibit osteoblast differentiation and activity. Specifically, in bone lysates from 
miR21Δot females, only SOST mRNA levels were reduced (Fig. 11a). On the other hand, in 
miR21Δot male bones, IL-1β, DKK1, and SOST mRNA expression was significantly 
decreased compared to miR21f/f mice (Fig. 11b).
Moreover, consistent with the sex-divergent effects of osteocytic-miR21 deletion on 
osteocyte cytokine production, sex-specific changes in several signaling pathways previously 
shown to be involved in regulating cytokine production and secretion were detected by 
Milliplex cell-signaling array analysis in bone lysates (Fig. 12a and Tables 3,4). Specifically, 
decreases in phosphorylated/total levels of ERK1/2 (−38%), STAT3 (−26%) and p38 (−28%) 
were detected in miR21Δot females, but not in males. Moreover, miR21Δot females exhibited 
a tendency towards increased phosphorylated/total NF-κB (+23%) levels. Further, while 
miR21Δot males exhibited increased phosphorylated/total p70S6K (+22%) levels, females 
exhibited a tendency towards decreased p70S6K (−15%) levels. On the other hand, 
osteocytic miR21 deficiency induced similar decreases in JNK signaling in both females 
(−35%) and males (−28%), although significance was only reached in female mice.
miR21 has sex-independent effects on bone mechanical properties.
Despite the sex-specific effects of osteocytic miR21 deficiency on bone cell activity and 
architecture, femoral bone mechanical properties were significantly higher in both female 
and male miR21ΔOt mice compared to the respective miR21f/f controls. In particular, in 
females, femur mechanical testing by 3-point bending detected significantly higher post-
yield and total displacement (+35% and +29%), post-yield and total work (+19% and 
+17%), as well as the post-yield material property total strain (+26%), in miR21Δot 
compared to miR21f/f mice (Table 5). No changes in the pre-yield mechanical properties at 
either the structural or material levels were detected in the female mice. In males, even 
greater increases were detected in post-yield and total displacement (+94% and +60%), post-
yield and total work (+71% and +56%), as well as the post-yield material properties, total 
strain and toughness (+56% and +28%) in miR21Δot compared to miR21f/f mice (Table 6). 
On the other hand, decreases in the pre-yield structural property, displacement to yield, and 
the pre-yield material property, yield stress, were detected in the male miR21Δot compared to 
miR21f/f mice. Taken together, these findings suggest that bones from miR21Δot mice are 
more ductile, providing a potential mechanical advantage since the bones are more tolerant 
to damage accrual and, thus, less brittle and less susceptible to fracture. Given differences 
exist both at the structural and material level, it suggests that fundamental differences in the 
properties of the matrix underlie the enhanced mechanical properties.
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There is growing evidence that osteocytes are key regulators of bone homeostasis and 
orchestrators of bone cell activity [1]. In previous studies, we showed that miR21 expression 
is low in the absence of osteocytic Cx43 and in old female mice, and low miR21 levels are 
responsible for the increase in osteocyte apoptosis in the Cx43-deficient cells [15]. 
Additionally, we demonstrated that osteocyte apoptosis directly promotes osteocyte cytokine 
production and stimulates osteoclast differentiation.
Here we offer additional insights into the role of miR21 in osteocytes. We now provide 
evidence that the miR21 locus exerts a sex-divergent role in osteocytes regulating bone 
mass/geometry through paracrine actions on osteoblasts and osteoclasts. Further, we reveal a 
potential mechanism by which miR21 removal from osteocytes differentially alters bone 
turnover by sex-specific regulation of key signaling pathways in osteocytes as well as 
cytokine production/secretion. Similar sex-divergent effects have been found in mice 
expressing a Cx43 mutant lacking the C-terminus domain [19,20]. Thus, female mice 
expressing the truncated Cx43 molecule exhibit decreased cancellous bone mass, but intact 
cortical bone [19], whereas males exhibit no change in cancellous bone but periosteal 
expansion, reduced thickness and increased porosity in cortical bone [20]. Interesting, we 
also demonstrate that despite the sex-divergent effects on osteocyte viability and bone 
turnover, osteocytic miR21 negatively influences bone mechanical properties in a sex-
independent manner.
Our studies also revealed a site specific consequence of osteocytic miR21 deletion, with 
different results when analyses were performed in cortical versus cancellous bone. Based on 
previous evidence that the DMP1-8kb-Cre transgene is expressed in both appendicular and 
axial skeleton [19,21-24], and on the fact that miR21 deletion alters bone cells and bone 
structure in both compartments, our data suggest that that the different effect of miR21 
deletion is due to intrinsic differences in the bones rather than differential miR21 expression. 
Nevertheless, future studies will be carried out to established the basis for the diverse 
consequences of osteocytic miR21 deletion.
In the current study, we demonstrate that miR21 deficiency reduces osteocyte viability and 
alters mitochondria gene expression in female mice. Consistent with this, in vitro inhibition 
of miR21 expression by transfecting a miR21 antagomir increases cell death in MLO-Y4 
osteocytic cells [15]. Further, adenovirus-Cre infection of miR21f/f calvaria bones leads to 
morphological changes in osteocytes consistent with apoptosis, as well as an increase in the 
expression of the apoptosis-associated genes, also reported here. These anti-apoptotic effects 
of miR21 are consistent with numerous studies showing that miR21 promotes cell survival 
by directly targeting and inhibiting FasL and PTEN [25-27]. In particular, we previously 
demonstrated that increases in osteocyte apoptosis in Cx43-deficient osteocytic cells and 
bones from old female mice, are due to low miR21 levels which increase PTEN levels and 
consequently reduce Akt signaling [15]. In cardiac tissue, miR21 has been shown to directly 
promote mitochondrial cytochrome B translation and reduce reactive oxygen species (ROS) 
production [28]. Additionally, miR21 promotes mitochondrial homeostasis and adaptation in 
mTORc1-activated cells [29]. Further, miR21 promotes cancer cell-survival by down-
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regulating PTEN and consequently activating the PI3K/AKT/mTOR pathway [30]. We also 
detected sex-dependent alterations in phosphorylated levels of the mTOR substrate, p70S6K, 
with higher p70S6K levels in males and trends towards lower Akt and p70S6K levels in 
female miR21Δot mice. Interestingly, consistent with our findings in miR21Δot males, several 
other studies have found that inhibition of miR21 protects against fibrosis by improving 
mitochondrial function [31,32]. Taken together these pieces of evidence highlight the 
possibility that miR21 regulation of mTORc1 signaling in osteocytes may underlie these 
sex-divergent effects on osteocyte viability and mitochondrial function, however, additional 
studies are needed to clearly elucidate these mechanisms.
miRs in general, and miR21 in particular, target a large number of genes, in a cell context-
dependent manner. Indeed, some of the genes included in our studies have already been 
shown to be targeted by miR21 regulation. Examples are the apoptosis- and mitochondria-
associated genes. It is not clear, however, whether the effects of miR21 on gene regulation 
are a direct consequence of altered transcription or an indirect regulation of expression 
downstream of other genes or even of intracellular kinases. Nevertheless, our findings 
highlight a novel sex-divergent role of miR21 in osteocytes and raise the possibility that 
similar sex-divergent miR21 regulation exists in other tissues.
Further, consistent with the effects of osteocytic miR21 removal on osteocyte viability, 
RANKL/OPG mRNA levels were only increased in bones from miR21Δot females. 
Surprisingly, despite the RANKL/OPG ratio changes osteoclast differentiation and 
resorption were attenuated in miR21Δot females, but elevated in miR21Δot males. Similar to 
our findings in miR21Δot females, Hu et. al, found that osteoclast function was inhibited in 
global miR21 deficient (miR21−/−) mice in spite of the fact that RANKL production and 
secretion were increased [33]. However, since mice were not separated by sex and because 
miR21, which is known to regulate osteoclast differentiation and survival [26,34], was 
globally deleted, it is unclear if the inhibitory effects on osteoclasts in this study were due to 
a lack of miR21 regulation in osteocytes or a direct result of miR21 deficiency in 
osteoclasts. In our study, we found that addition of osteocyte-enriched bone culture CM 
from miR21Δot females suppressed osteoclasts, whereas CM from miR21Δot males 
stimulated osteoclasts, suggesting that these effects are due to the lack of miR21 in 
osteocytes. Furthermore, the fact that these results occurred independently of whether 
female or male BMCs were used, suggests that the sex-specific effects of osteocytic miR21 
removal on osteoclasts are due to miR21 regulation in osteocytes rather than direct effects on 
osteoclasts.
In addition, miR21 regulation in osteoblasts has been shown to promote differentiation and 
mineralization [35]. Consistent with this, osteoblast differentiation and activity were altered 
in miR21−/− mice [33]. When cultured ex vivo osteogenic differentiation potential of 
miR21−/− BMCs was decreased, while colony forming efficiency and proliferation rates 
were increased. Interestingly, despite these changes, osteoblast number and activity were 
unaltered in vivo, possibly because mice of both sexes were combined in the in vivo study. 
We now report that osteocytic miR21 deletion also altered osteoblast number and activity in 
a sex- and site-dependent manner. Further, consistent with the effects on bone cell 
differentiation and activity, osteocytic miR21 deficiency induced sex- and compartment-
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specific effects on bone mass and architecture. Future studies will be performed to determine 
whether the mild effect of miR21 deletion on bone mass and architecture is exacerbated with 
aging.
Based on the non-cell autonomous effects on osteoclasts and osteoblasts detected in the 
miR21Δot mice, we next investigated the effects of miR21 regulation on osteocyte cytokine 
production and release. Consistent with the sex-dimorphic effects on osteoclasts and 
osteoblasts we found that mRNA levels of several cytokines were reduced in bones from 
female, but not male miR21Δot mice. On the other hand, we detected decreases in the mRNA 
levels of IL-1β and DKK1, which negatively regulate osteoblast differentiation and activity, 
in bones from miR21Δot males, but not females. Further, in CM from miR21Δot bones, M-
CSF and VEGF protein levels were increased in males, but showed tendencies towards 
decrease in females. Additionally, given the changes in IL-6 expression detected at the 
mRNA level it is also possible that IL-6 levels are altered in the miR21Δot CM, however 
because the levels were greater than the standard use in the multiplex assays we were unable 
to measure them. Interestingly, we also found several cytokines exhibited an opposite pattern 
of expression in serum compared to CM from miR21Δot bones, suggesting that that removal 
of osteocytic miR21 exerts non-cell autonomous effects on osteoclasts and osteoblasts by 
locally rather than systemically altering osteocyte-derived cytokine levels.
In addition, osteocytic miR21 deficiency altered osteocyte signaling pathways in a sex-
dependent manner. Interestingly, several signaling pathways that are regulated by previously 
identified miR21 target genes were downregulated in miR21Δot females, but not males, as 
illustrated in Fig. 12a. In particular, phosphorylated ERK1/2, p38, and STAT3 levels were 
significantly reduced, whereas, phosphorylated NF-κB levels showed tendencies towards 
increase in miR21Δot female bones. Consistent with these findings, previous studies have 
shown that miR21 directly targets inhibitors of ERK1/2 (Spry1/2), p38 (SMAD7) and 
STAT3 (PIAS3) [35-37]. Additionally, miR21 targets PDCD4, which in turn activates NF-
κB signaling [33,38]. Nevertheless, while these findings suggest that miR21 regulates 
osteocyte signaling pathways and cytokine production/secretion in sex-specific manner, 
additional studies are required to clearly elucidate the molecular events mediating these 
autocrine and paracrine effects of osteocytic miR21 on bone metabolism.
Alterations in miR21 expression have been detected in numerous diseases. However, the 
tissue-specific roles of miR21 under physiological and pathological conditions remains 
unclear. In some cases miR21 has been shown to promote disease progression, while in 
others miR21 is protective [39,40]. While there are several potential explanations for the 
varying results regarding the role of miR21 in different tissues under normal and disease 
conditions, given the findings of our present study, it is possible that the differential effects 
of miR21 are due to the sex-dependent roles of miR21. Consistent with this notion, work by 
Queirós et. al, detected sex differences in the expression of several miRs including miR21, 
as well as, miR24, miR27a, miR27b, miR106a and miR-106b that negatively regulate 
MAPK/ERK signaling in the heart [41]. Additionally, this study showed that estrogen 
modulates the expression of these miRs in a sex-specific manner via estrogen receptor (ER) 
β. Further, in bone, studies have shown that induction of miR21 during osteoclastogenesis 
preserves survival through negative regulation of FasL and estrogen stimulates osteoclast 
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apoptosis by antagonizing miR21 [26]. Indeed, given the increasing number of 
pharmaceutical companies working to develop miR-based drugs combined with the growing 
number of studies identifying gender-dependent adverse drug reactions [42], our findings 
highlight the importance of considering sex-dependent miR roles when developing 
therapeutics.
Interestingly, despite these sex-specific effects of osteocytic miR21 deficiency, both female 
and male miR21ΔOt mice exhibited markedly higher femoral cortical bone mechanical 
properties compared to the respective miR21f/f controls. In particular, our findings that 
osteocytic miR21 deficiency enhanced the femur post-yield mechanical properties, suggest 
that bones from miR21Δot mice are more ductile, providing a potential mechanical 
advantage since the bones are more tolerant to damage accrual and, thus, less brittle and less 
susceptible to fracture. As improvements in mechanical properties cannot be accounted for 
by the alterations observed at the cellular and structural level, it is likely that they result from 
differences in the matrix itself. Traditionally, alterations in post-yield properties are due to 
collagen structure/cross-linking. In future studies, we will work to uncover the molecular 
and tissue-level mechanisms by which osteocytic miR21 negatively influences bone 
mechanical integrity.
Moreover, consistent with these negative sex-equivalent effects of miR21 on bone 
mechanical properties, several studies have found that miR21 levels are upregulated in 
serum, bone tissue, and bone cells (osteoblasts and osteoclasts) of osteoporotic patients 
compared to controls [43]. Additionally, miR21 levels were strongly inversely correlated 
with BMD and fracture incidence in osteoporotic patients. Thus, our findings that removal of 
osteocytic miR21 enhances bone biomechanical properties in both sexes, suggest a 
therapeutic potential of miR21 antagomir treatment to prevent bone fragility in aging in 
females and males. Further, given the fact that altered miR21 expression is most commonly 
seen under pathological conditions, our results provide a basis for future studies to test 
whether osteocytic miR21 deficiency protects against bone loss induced by sex-steroid 
deficiency, unloading, or aging.
Collectively, our findings provide evidence that the miR21 locus exerts both sex-divergent 
and sex-equivalent roles in osteocytes. miR21 directly regulates cell viability/mitochondrial 
function in osteocytes and subsequently alters bone metabolism and architecture through 
paracrine actions on osteoblasts and osteoclasts in a different manner in males and females. 
However, despite these sex-dependent effects, removal of osteocytic miR21 enhances bone 
mechanical properties in both sexes. Overall, our findings provide novel insights into the 
sex-dependent and -independent mechanisms by which miR21 regulation in osteocytes alters 
bone (Fig. 12b), which offer a basis for future studies that could eventually lead to new 
therapeutic targets to treat bone fragility.
Materials and Methods
Mice
miR21 floxed mouse strain was engineered with lox cassettes on both sides of the mmu-
miR-21 genomic locus (named miR21f/f) [15], and crossed with DMP1-8kb-Cre mice [44] 
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to obtain female and male miR21f/f and miR21f/f;DMP1-8kb-Cre (miR21Δot) mice. All mice 
were of the C57BL/6 background, fed a regular diet and water ad libitum and maintained on 
a 12h light/dark cycle. The protocols involving mice were approved by the Institutional 
Animal Care and Use Committee of Indiana University School of Medicine.
RNA extraction and qRT-PCR
Total RNA was isolated using TRIzol (Invitrogen, Grand Island, NY) [45]. Reverse 
transcription was performed using a high-capacity cDNA kit (Applied Biosystems, Foster 
City, CA). qPCR was performed using the Gene Expression Assay Mix TaqMan Universal 
Master Mix with an ABI 7900HT real-time PCR system. Gene expression was corrected by 
the levels of the house-keeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
Primers and probes were commercially available (Applied Biosystems, Foster City, CA) or 
were designed using the Assay Design Center (Roche Applied Science, Indianapolis, IN). 
Expression levels of miR21 (assay ID:000397) and the housekeeping miR135 (assay 
ID:001230) were evaluated as published [15]. Relative expression was calculated using the 
ΔCt method.
Body weight and bone mineral density (BMD) by dual energy x-ray absorptiometry (DXA)
BMD was measured monthly from 1 to 4 months of age by DXA/PIXImus (G.E. Medical 
Systems, Lunar Division, Madison, WI) [45]. Body weight was measured at the time of the 
DXA scan. BMD measurements included total (whole body excluding the head and tail), 
femoral (entire femur) and spinal (L1-L6 lumbar vertebrae) BMD. Calibration was 
performed using a standard control phantom before scanning, as recommended by the 
manufacturer.
μCT analysis
Femur and L4 vertebra were harvested from 4-month-old mice. Female bones were scanned 
using the Scanco μCT-35 system (Scanco Medical AG, Brüttisellen, Switzerland) using a 
50kV source, 120 mA, 151 milliseconds integration time, and 10μm voxel resolution [45]. 
Male bones were scanned using a 65kV source, 0.5mm Al filter, 0.7 degree rotation and 
two-image averaging with an isotropic voxel size of 9μm using a SkyScan 1176 system 
(SkyScan, Kontich, Belgium) [46]. Two different systems were used due to constrained 
instrument availability. The terminology and units used for μCT are those recommended by 
the American Society for Bone and Mineral Research (ASBMR) [47].
Bone histomorphometry
Femur and vertebra from 4-month-old mice were fixed in 10% neutral buffered formalin and 
embedded using previously established methods at the ICMH Histology and 
Histomorphometry Core [46]. To allow for dynamic histomorphometry mice were injected 
intraperitoneally with calcein (20 mg/kg; Sigma) and alizarin red (20 mg/kg; Sigma) 7 and 2 
days prior to sacrifice, respectively. Dynamic histomorphometry was performed on 
unstained methyl methacrylate-embedded L1-L3 vertebra (sagittal) and femur mid-diaphysis 
(transverse) sections using an epifluorescence microscope. Osteoclasts were quantified in 
TRAPase/Toluidine blue stained femur mid-diaphysis and vertebra sections and osteoblasts 
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in von Kossa/McNeal stained-sections. Histomorphometric analysis was performed using 
OsteoMeasure high resolution digital video system (OsteoMetrics Inc., Decatur, GA, USA). 
The terminology and units used are those recommended by the ASBMR Histomorphometry 
Nomenclature Committee [48].
Biomechanical testing
Three-point bending testing of the femoral mid-diaphysis was performed as published, using 
a servo-hydraulic test system (TestResources Inc., Shakopee, MN, USA) [19,46]. Femora 
were loaded until failure in an anterior–posterior direction with the upper contact area at the 
mid-diaphysis (50% total bone length) and the bottom contact points centered around this 
point and separated by 8mm. Cross-sectional moment of inertia and anterior–posterior 
diameter were determined by μCT and were used to calculate material-level properties [19].
Ex vivo bone organ cultures
Long bones were isolated from 2-month-old miR21f/f and miR21Δot mice. Bone-marrow 
cells (BMCs) were flushed out with α- MEM and osteocyte-enriched long bones were 
cultured ex vivo in 10% FBS and 1% penicillin/streptomycin (P/S)-α-MEM supplemented 
for 48h. Conditioned media was collected and stored at −20°C until used for the 
osteoclastogenesis assays and cytokine arrays.
Osteoclast assays
BMCs were isolated from C57BL/6 mice by flushing the bone marrow out with 10% FBS 
and 1% P/S-α-MEM and cultured for 48h [15,45]. Next, non-adherent cells were collected 
and 2×104cells/cm2 were seeded on 96-well plates and cultured with conditioned media 
collected from ex vivo cultures of osteocyte-enriched marrow-flushed long bones from 
miR21f/f and miR21Δot mice. Additionally, BMCs isolated from the miR-21f/f and miR21Δot 
mice were cultured in 10% FBS and 1% P/S-α-MEM for 48h. Next, non-adherent cells were 
collected and 2×104cells/cm2 were seeded on 96-well plates. RANKL (80ng/ml) and M-CSF 
(20ng/ml) were added to induce osteoclast differentiation and media was changed every 3 
days for 7 days. Cells were stained using a TRAPase kit (Sigma-Aldrich) and mature 
osteoclasts exhibiting 3 or more nuclei were quantified. Images were acquired using a Zeiss 
Axiovert 35 microscope equipped with a digital camera. Osteoclast size and number of 
nuclei were quantified using ImageJ.
Multiplex cytokine and cell-signaling assays
Cytokines in serum and conditioned media from osteocyte-enriched ex vivo bone organ 
cultures of miR21f/f and miR21Δot mice, were measured using the Bioplex protein array 
system at the Multiplex analysis core at IUSM. For the cytokine assay, premixed magnetic 
beads of the Milliplex mouse cytokine/chemokine 32 plex kit was used (Milliplex, 
Burlington, MA). Cell-signaling pathway alterations induced by deletion of osteocytic 
miR21 were examined in miR21f/f and miR21Δot calvaria bone lysates. For the cell-signaling 
assays, premixed magnetic beads of the Milliplex multi-pathway 9-plex phospho- and total 
protein kits were used.
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Cell culture and lentiviral transfection
miR21-silenced MLO-Y4 osteocytic cells were generated using short hairpin (sh)RNA 
Lentiviral Particles (Sigma-Aldrich Chemical Co., St. Louis, MO, USA), as previously 
reported,[5,44] and cultured as previously described. MLO-Y4 osteocytic cells silenced or 
not for Cx43 were plated at the density of 2 × 104 cells/cm−2 on 48-well plates coated with 
type I rat tail collagen and cultured overnight. Cells were transiently transfected using 
Lipofectamine RNAiMAX reagent (Invitrogen) containing miRIDIAN negative control 
inhibitor, miR21 inhibitor, negative control mimic, or miR21 mimic (GE Healthcare Bio-
Sciences, Pittsburgh, PA, USA) at a final concentration of 0.1 nM in medium without serum 
and penicillin/ streptomycin for 6 h. Next, 2x concentrated medium was added to each well 
and then cultured overnight. Medium was changed to a regular growing medium, and cells 
were then cultured for an additional 24 h before isolating mRNA. miR21 levels were 
decreased by 60% in MLO-Y4 scramble cells and by 91% in MLO-Y4 Cx43 shRNA cells 
treated with miR21 inhibitor, as measured by qPCR. miR21 levels were increased by 44% in 
MLO-Y4 scramble cells and 234% in MLO-Y4 Cx43 shRNA cells treated with the miR21 
mimic.
Whole-mount skeletal staining
Cartilage and mineralized tissue were analyzed in 6-day old newborn mice using alizarin 
red/alcian blue staining, as previously published [49].
Circulating metabolites
Blood was collected by cheek bleeding after 6 hours of fasting. Plasma was separated, 
aliquoted, and stored at −80 °C until used. Plasma N-terminal propeptide of type I 
procollagen (P1NP) (Immunodiagnostic Systems Inc., Fountain Hill, AZ, USA, 
cat.#AC-33F1) and C-telopeptide fragments (CTX) (cat.#AC-06F1) were measured as 
described by the manufacturer. Alkaline phosphatase (ALP) activity was assessed by a 
standard automated method using a Randox Daytona chemical analyzer (Northern Ireland, 
United Kingdom).
Statistical analysis
Data were analyzed using SigmaPlot (Systat Software Inc., San Jose, CA). Data are reported 
as mean ± SD. Data were evaluated by Student’s t-test or two-way ANOVA and differences 
with p<0.05 were considered statistically significant.
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GADH glyceraldehyde 3-phosphate dehydrogenase
DXA dual-energy X-ray absorptiometry
BMD bone mineral density
ASBMR American Society for Bone and Mineral Research
BMCs bone marrow cells
P/S penicillin/streptomycin
FBS fetal bovine serum
RANKL receptor activator of nuclear factor κ ligand, M-CSF, macrophage-
colony stimulating factor
TRAPase tartrate-resistant acid phosphatase
sh short hairpin
qPCR quantitative polymerase chain reaction
P1NP N-terminal propeptide of type I procollagen
ALP alkaline phosphatase
VMP1 vacuole membrane protein-1
MS/BS mineralized surface per total bone surface
BFR/BS bone formation rate per bone surface
MAR mineral apposition rate
N.Oc/BS osteoclast number per bone surface
Oc.S/BS osteoclast surface per bone surface
N.Ob/BS osteoblast number per bone surface
Ob.S/BS osteoblast surface per bone surface
TA tissue area
BA bone area
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Figure 1. Sex-dependent miR21 regulation of osteocyte viability and mitochondrial function.
(a) Scheme illustrating generation of mouse model with osteocyte-targeted miR21 deletion. 
(b) miR-21 levels in calvaria bones from female and male miR21f/f and miR21Δot mice by 
qPCR and corrected by miR135 (n= 10-14). mRNA levels of vacuole membrane protein-1 
(VMP1) measured in calvaria bones from female and male miR21fl/fl and miR21Δot mice. 
Bars represent mean ± s.d., *p<0.05 versus miR21f/f mice, #p<0.05 versus miR21f/f females, 
by two-way ANOVA (for miR21) or by t-test (for VMP1). (c) RANKL and OPG levels and 
(d) mRNA expression of apoptosis-associated genes measured in calvaria bones from female 
miR21f/f and miR21Δot mice (n= 10-14). (e) RANKL and OPG levels and (f) mRNA 
expression of apoptosis-associated genes measured in calvaria bones from male miR21f/f 
and miR21Δot mice (n= 10). Bars represent mean ± s.d., *p<0.05 versus miR21f/f, by t-test.
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Figure 2. miR21 maintains osteocyte viability and regulates RANKL/OPG levels in control and 
Cx43-deficient MLO-Y4 osteocytic cells.
RANKL and OPG levels and apoptosis-associated gene expression (Gadd153, Foxo3, and 
P27) in miR-21 (a) antagomir and (b) mimic transfected MLO-Y4 osteoctyic cells, and in 
miR-21 (c) antagomir and (d) mimic transfected MLO-Y4 osteoctyic cells silenced for 
Cx43. Bars represent mean ± s.d., *p<0.05 versus negative control, by t-test.
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Figure 3. deletion of miR21 from osteocytes differentiatly regulate mitochodrial genes in female 
and male miR21Δot mice.
mRNA expression of mitochondrial genes in calvaria bones from (a) female and (b) male 
miR21f/f and miR21Δot mice (n= 10). Bars represent mean ± s.d., *p<0.05 versus negative 
control, by t-test.
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Figure 4. Removal of osteocytic miR21 regulates body weight and bone mass accrual in a sex-
dependent manner.
a. Representative images of whole body preparations (n=3/genotype) stained by Alcian blue/
alizarin red in 7-day-old mice for evaluation of cartilage (blue) and calcified tissue 
(magenta). Scale bars indicate 1 cm (for whole body) or 0.5 cm (for forelimb, hindlimb, and 
tail). Body weight, and total, spinal and femoral BMD (DXA) were assessed monthly from 1 
to 4 months of age in (b) female and (c) male miR21f/f and miR21Δot mice (n=12-16). Bars 
represent mean ± s.d., *p<0.05 versus miR21f/f at the same age, by t-test.
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Figure 5. Osteocytic-miR21 deletion leads to sex-specific changes in femoral cortical bone 
turnover and architecture.
(a-b) Mineral apposition rate (MAR), mineralizing surface (MS)/BS, and bone formation 
rate (BFR)/BS were measured in unstained cross-sections of the femoral mid-diaphysis on 
the endosteal and periosteal surfaces of (a) female and (b) male miR21f/f and miR21Δot mice 
(n=9-10). Representative fluorescent images are shown, scale bar indicates 25μm. (c-d) 
Osteoclast number (N.Oc)/BS and surface covered by osteoclasts (Oc.S)/BS were scored on 
the endosteal surface of femoral mid-diaphysis bone sections stained for TRAPase/T. blue of 
(c) female and (d) male miR21f/f and miR21Δot mice (n=10). Representative images from 
osteoclasts on the bone surface (magenta, arrow) are shown, scale bar indicates 25μm. (e-f) 
Cortical bone geometry in the femoral mid-diaphysis of (e) female and (f) male miR21f/f and 
miR21Δot mice was assessed by μCT (n=12). Representative reconstructed images are 
shown. Bars represent mean ± s.d., *p<0.05 versus miR21f/f, by t-test.
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Figure 6. Osteocytic miR21 deficiency suppresses bone turnover in female mice.
Circulating markers of bone resorption (CTX, n=10-15) and formation (P1NP, 10-14 and 
ALP, n=10-12) measured in serum of 4-month-old female miR21f/f and miR21Δot mice by 
ELISA.
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Figure 7. Sex-dependent alterations in vertebral cancellous bone turnover and architecture 
induced with removal of osteocytic-miR21.
(a-f) Number of osteoblasts (N.Ob)/BS and bone surface covered by osteoblasts (Ob.S)/BS 
were scored in lumbar vertebra from (a) female and (d) male miR21f/f and miR21Δot mice 
bone sections stained with von Kossa/McNeal (n=7-10). Representative images of 
osteoblasts are shown, scale bar indicates 25μm. Mineral apposition rate (MAR), 
mineralizing surface (MS)/BS, and bone formation rate (BFR)/BS measured in unstained 
sections of the lumbar vertebra from (b) female and (e) male miR21f/f and miR21Δot mice 
(n=8-10). Representative fluorescent images are shown, scale bar indicates 25μm. Osteoclast 
number (N.Oc)/BS and surface covered by osteoclasts (Oc.S)/BS were scored on the 
cancellous bone surface of the lumbar vertebra from (c) female and (f) male miR21f/f and 
miR21Δot mice stained for TRAPase/T. blue (n=9-10). Representative images from 
osteoclasts on the bone surface (magenta, arrow) are shown, scale bar indicates 25μm. (g-h) 
Analysis of cancellous bone microarchitecture in L4 vertebra from (g) female and (h) male 
miR21f/f and miR21Δot mice assessed by μCT (n=12-14). Representative 3D images of 
vertebral cancellous bone are shown. Bars represent mean ± s.d., *p<0.05 versus miR21f/f, 
by t-test.
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Figure 8. Removal of osteocytic alters distal femur cancellous architecture in a sex-dependent 
manner.
Analysis of the distal femur cancellous bone microarchitecture of female and male miR21f/f 
and miR21Δot mice was assessed by μCT (n=12-14). Bars represent mean ± s.d., *p<0.05 
versus miR21f/f, by t-test.
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Figure 9. Sex-specific regulation of osteoclast differentiation following osteocytic-miR21 removal.
(a-b) Non-adherent BMCs harvested from female and male miR21f/f and miR21Δot were 
differentiated into osteoclasts with RANKL/M-CSF for 7 days. Osteoclast number per well, 
average osteoclast size and number of nuclei per osteoclast were scored for (a) female and 
(b) male miR21f/f and miR21Δot non-adherent BMCs (n=4). Representative images from 
mature osteoclasts stained for TRAPase are shown, scale bar indicates 100μm. (c) 
Illustration of experimental design in which non-adherent BMCs isolated from wild-type 
C57BL/6 mice were treated with CM from ex vivo cultures of long bones from female and 
male miR21f/f and miR21Δot and supplemented with RANKL/M-CSF for 7 days. (d-e) 
Osteoclast number per well, average osteoclast size and number of nuclei per osteoclast 
were scored for female non-adherent BMCs treated with CM from (d) female and (e) male 
miR21f/f and miR21Δot (n=6). Representative images from mature osteoclasts stained for 
TRAPase are shown, scale bar indicates 100μm. (f-g) mRNA expression of pro-
inflammatory cytokine genes in calvaria bones from (f) female and (g) male miR21f/f and 
miR21Δot mice. (h-i) Pro-inflammatory cytokine protein levels in CM from ex vivo marrow-
flushed osteocyte enriched bone cultures from (h) female and (i) male miR21f/f and 
miR21Δot mice, measured by Milliplex cytokine array. Bars represent mean ± s.d., *p<0.05 
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versus miR21f/f, by t-test. (J) Illustration of the proposed model by which removal of 
osteocytic miR21 modulates pro-inflammatory cytokine production and osteoclast 
differentiation.
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Figure 10. Sex-specific regulation of osteoclast differentiation following osteocytic-miR21 
removal.
Osteoclast number per well and gene expression levels were measured in non-adherent 
BMCs treated with 25% conditioned media from (a) female and (b) male miR21f/f and 
miR21Δot (n=6). Bars represent mean ± s.d., *p<0.05 versus miR21f/f, by t-test. 
Representative images from mature osteoclasts stained for TRAPase are shown, scale bar 
indicates 100μm.
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Figure 11. Sex-dependent decreases in anti-osteoblastic cytokine mRNA levels in the absence of 
osteocytic miR21.
mRNA levels of IL-1β, DKK1, and SOST measured in calvaria bones from (a) female and 
(b) male miR21f/f and miR21Δot mice (n=10). Bars represent mean ± s.d., *p<0.05 versus 
miR21f/f, by t-test.
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Figure 12. Proposed autocrine and paracrine effects of osteocytic miR21 removal.
(a) Figure illustrating the sex-specific regulation of key cell-signaling pathways in 
osteocytes by miR21, in turn, leads to sex-dependent alterations in osteocyte viability and 
mitochondrial function. Previously identified miR21 targets are shown in grey and proteins 
altered in the current study are shown in black. Direction of changes in protein levels are 
indicated using arrows for miR21Δot female (pink) and male (green) mice. (b) Working 
model showing the proposed sex-dependent mechanisms by which miR21 regulation in 
osteocytes alters bone metabolism and geometry through paracrine actions on osteoblasts 
and osteoclasts. At the same time, removal of osteocytic miR21 enhances bone mechanical 
properties in a sex-independent manner.
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Table 1.
Cytokines in conditioned media from female miR21Δot mice.
miR21f/f miR21Δot % change p-value
IL-6 OOR> OOR>
Eotaxin 16.63 ± 14.14 6.81 ± 1.52 −59.05 0.12
IFN-g 2.78 ± 0.60 1.88 ± 1.40 −32.43 0.27
IL-1a 19.86 ± 9.73 4.67 ± 4.89 −26.16 0.27
IL-2 OOR< OOR<
IL-3 OOR< OOR<
IL-4 1.15 ± 0.41 1.00 ± 0.25 −12.88 0.47
IL-5 13.99 ± 6.58 9.66 ± 2.73 −30.94 0.17
IL-7 OOR< OOR<
IL-9 133.69 ± 41.57 126.19 ± 22.48 −5.61 0.71
IL-10 5.11 ± 2.24 3.55 ± 1.06 −30.60 0.15
IL-12(p40) OOR< OOR<
IL-12(p70) 13.48 ± 6.96 13.34 ± 4.45 −1.03 0.97
IL-13 OOR< OOR<
IL-15 4.05 ± 2.50 6.00 ± 3.53 47.96 0.46
IP-10 117.55 ± 48.07 70.89 ± 49.31 −39.69 0.15
LIF 358.56 ± 202.19 326.44 ± 127.57 −8.96 0.75
LIX 63.85 ± 58.73 40.30 ± 19.16 −36.88 0.37
M-CSF 12.70 ± 8.09 6.7 ± 2.54 −51.44 0.09
MIG 109.53 ± 38.44 86.11 ± 18.64 −21.38 0.21
MIP-1β 48.52 ± 31.58 26.94 ± 5.81 −44.47 0.13
MIP-2 45.33 ± 14.96 44.95 ± 13.45 −0.84 0.97
G-CSF 1127.08 ± 931.54 1026.83 ± 595.91 −8.89 0.83
IL-1β 9.52 ± 6.59 8.66 ± 2.21 −9.15 0.77
IL-17 1.00 ± 0.60 0.91 ± 0.43 −9.47 0.76
KC 379.31 ± 656.65 269.09 ± 302.65 −29.06 0.72
MCP-1 607.36 ± 615.80 264.68 ± 130.32 −56.42 0.21
MIP-1α 36.17 ± 13.52 29.95 ± 6.53 −17.21 0.34
RANTES OOR< OOR<
TNF-α 7.84 ± 6.71 4.28 ± 1.03 −45.39 0.23
GM-CSF 23.13 ± 12.14 19.84 ± 6.10 −14.21 0.57
VEGF 204.67 ± 110.32 132.28 ± 25.83 −35.37 0.15
*
p<0.05 versus miR-21f/f mice, by t-test (n=3-6). Values outside the standard curve are denoted by “OOR<” or “OOR>” (Out of Range).
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Table 2.
Cytokines in conditioned media from male miR21Δot mice.
miR21f/f miR21Δot % change p-value
IL-6 OOR> OOR>
Eotaxin 8.22 ± 6.34 6.43 ± 4.13 −21.81 0.57
IFN-g 2.70 ± 0.58 2.54 ± 1.05 −6.06 0.75
IL-1a 15.90 ± 2.24 13.06 ± 4.64 −17.88 0.21
IL-2 OOR< OOR<
IL-3 OOR< OOR<
IL-4 0.94 ± 0.20 0.82 ± 0.13 −13.25 0.23
IL-5 8.55 ± 2.52 6.01 ± 1.69 −29.77 0.07
IL-7 OOR< OOR<
IL-9 122.17 ± 18.99 142.73 ± 18.89 16.84 0.09
IL-10 4.88 ± 3.10 3.37 ± 0.82 −30.94 0.28
IL-12(p40) OOR< OOR<
IL-12(p70) 16.24 ± 3.16 14.74 ± 4.05 −9.29 0.49
IL-13 OOR< OOR<
IL-15 3.78 ± 2.44 5.80 ± 6.45 53.63 0.53
IP-10 46.00 ± 17.06 76.65 ± 57.81 64.44 0.26
LIF 432.25 ± 99.60 422.48 ± 178.49 −2.26 0.91
LIX 61.89 ± 14.19 41.35 ± 20.70 −33.19 0.07
M-CSF 4.45 ± 0.97 7.11 ± 1.81 59.64* 0.01
MIG 75.46 ± 18.73 83.83 ± 26.69 11.10 0.54
MIP-1β 27.84 ± 5.88 23.54 ± 1.77 −15.44 0.12
MIP-2 56.2 ± 16.81 38.11 ± 12.07 −32.19 0.06
G-CSF 1576.48 ± 377.85 1029.03 ± 1013.82 −34.73 0.24
IL-1β 9.56 ± 3.46 9.75 ± 2.73 1.99 0.92
IL-17 1.14 ± 0.23 1.04 ± 0.48 −9.20 0.64
KC 269.79 ± 160.04 97.42 ± 99.26 −63.89 0.06
MCP-1 443.16 ± 243.87 184.39 ± 154.34 −58.39 0.05
MIP-1α 29.1 ± 3.34 28.18 ± 3.75 −53.15 0.66
RANTES OOR< OOR<
TNF-α 4.48 ± 0.34 4.29 ± 0.57 −4.17 0.50
GM-CSF 24.80 ± 3.05 21.60 ± 6.18 −12.88 0.28
VEGF 117.78 ± 15.83 176.17 ± 42.68 49.58* 0.01
*
p<0.05 versus miR-21f/f mice, by t-test (n=5-6). Values outside the standard curve are denoted by “OOR<” or “OOR>” (Out of Range).
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Table 3.
Phosphorylated/total protein levels measured by 9-Plex cell-signaling array in bones from female miR21Δot 
mice.
miR21f/f miR21Δot % change p-value
CREB 0.012 ± 0.002 0.012 ± 0.005 0.56 0.98
JNK 0.390 ± 0.123 0.298 ± 0.04 −35.44 0.03
NF-κB 0.024 ± 0.002 0.030 ± 0.005 22.68 0.06
ERK 1/2 0.034 ± 0.009 0.021 ± 0.006 −37.81 0.03
AKT 0.851 ± 0.297 0.745 ± 0.158 −12.54 0.49
P70S6K 0.245 ± 0.054 0.209 ± 0.041 −14.52 0.23
STAT3 0.055 ± 0.013 0.040 ± 0.011 −27.65 0.05
STAT5 0.577 ± 0.121 0.576 ± 0.086 −0.253 0.98
P38 0.533 ± 0.071 0.392 ± 0.113 −26.48 0.03
*
p<0.05 versus miR-21f/f mice, by t-test (n=5-6)
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Table 4.
Phosphorylated/total protein levels measured by 9-Plex cell-signaling array in bones from male miR21Δot 
mice.
miR21f/f miR21Δot % change p-value
CREB 0.011 ± 0.005 0.011 ± 0.002 −0.76 0.97
JNK 0.424 ± 0.128 0.295 ± 0.089 −27.58 0.11
NF-κB 0.028 ± 0.006 0.028 ± 0.006 −1.29 0.92
ERK 1/2 0.037 ± 0.017 0.031 ± 0.009 −16.22 0.46
AKT 0.610 ± 0.085 0.605 ± 0.088 −0.79 0.93
P70S6K 0.241 ± 0.045 0.294 ± 0.028 21.87 0.04
STAT3 0.046 ± 0.018 0.050 ± 0.010 8.08 0.67
STAT5 0.585 ± 0.155 0.526 ± 0.041 −10.02 0.39
P38 0.540 ± 0.127 0.575 ± 0.122 6.37 0.64
*
p<0.05 versus miR-21f/f mice, by t-test (n=5-6)
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Table 5.
Mechanical strength in cortical bone in female miR21Δot mice.
miR21f/f miR21Δot % change
Yield Force (N) 8.978 ± 0.602 8.66 ± 0.486 −3.53
Ultimate Force (N) 11.662 ± 1.013 11.628 ± 1.168 −0.29
Pre-Yield Displacement (μm) 215.073 ± 22.801 221.153 ± 23.920 2.83
Post-yield Displacement (μm) 981.928 ± 380.192 1328.576 ± 292.795* 35.30
Total Displacement (μm) 1197.002 ± 376.015 1549.729 ± 285.952* 29.47
Stiffness (N/mm) 47.874 ± 6.39 45.632 ± 4.105 −4.68
Pre-yield Work (mJ) 1.049 ± 0.171 1.019 ± 0.1349 −2.82
Post-yield Work (mJ) 8.200 ± 1.991 9.791 ± 1.303* 19.40
Total Work (mJ) 9.249 ± 1.910 10.811 ± 1.298* 16.88
Yield Stress (MPa) 36.905 ± 4.038 35.253 ± 4.983 −4.48
Ultimate Stress (MPa) 47.798 ± 4.570 47.076 ± 5.806 −1.51
Pre-yield Strain (με) 19432.98 ± 1646.98 19533.12 ± 2215.71 0.52
Total Strain (με) 108546.8 ± 34714.9 137001.5 ± 27440.5* 26.21
Modulus (GPa) 2.156 ± 0.195 2.094 ± 0.239 −2.89
Resilience (MPa) 0.391 ± 0.077 0.368 ± 0.080 −5.74
Toughness (MPa) 3.449 ± 0.818 3.875 ± 0.660 12.33
*
p<0.05 versus miR-21f/f mice, by t-test (n=10-12)
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Table 6.
Mechanical strength in cortical bone in male miR21Δot mice.
miR21f/f miR21Δot % change
Yield Force (N) 11.086 ± 1.858 10.032 ± 2.292 −9.51
Ultimate Force (N) 13.039 ± 1.500 13.507 ± 1.276 3.59
Pre-Yield Displacement (μm) 306.050 ± 57.920 257.687 ± 50.334* −15.80
Post-yield Displacement (μm) 511.277 ± 191.202 992.232 ± 372.887* 94.07
Total Displacement (μm) 786.897 ± 124.494 1260.106 ± 366.007* 60.14
Stiffness (N/mm) 42.591 ± 4.177 44.465 ± 4.182 4.40
Pre-yield Work (mJ) 1.654 ± 0.533 1.249 ± 0.538 −24.49
Post-yield Work (mJ) 5.563 ± 1.693 9.537 ± 2.676* 71.43
Total Work (mJ) 6.981 ± 1.325 10.879 ± 2.793* 55.83
Yield Stress (MPa) 84.042 ± 14.228 70.200 ± 17.563* −16.47
Ultimate Stress (MPa) 98.449 ± 7.539 94.338 ± 7.406 −4.18
Pre-yield Strain (με) 44489.068 ± 8781.447 38232.606 ± 7489.234 −14.06
Total Strain (με) 119759.5 ± 24724.3 186827.1 ± 56494.9* 56.00
Modulus (GPa) 2.237 ± 0.163 2.067 ± 0.299 −7.62
Resilience (MPa) 1.813 ± 0.545 1.037 ± 0.272* −42.78
Toughness (MPa) 9.095 ± 3.038 11.635 ± 2.375* 27.92
*
p<0.05 versus miR-21f/f mice, by t-test (n=10-12).
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